Drug
L19il2
L19il2: highest development phase Phase 2, developed by Philogen S.p.A.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Philogen S.p.A.
Trials
| Drug | Phase | Indication |
|---|---|---|
| L19IL2 NCT07227350 | Phase 2 | Locally Advanced Basal Cell Carcinoma |
Latest
No recent events.
Follow L19il2 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.